Intranasal Administration

Overview

Intranasal administration is a method of delivering substances through the nasal cavity, where they are absorbed across the nasal mucosa into the systemic circulation or, in some cases, transported directly to the central nervous system (CNS) via the olfactory and trigeminal nerve pathways. This needle-free route has attracted significant interest for peptide delivery because it avoids the enzymatic degradation of the gastrointestinal tract and the first-pass hepatic metabolism that limits oral administration.

The nasal cavity offers a large surface area (approximately 150 cm2), a thin and highly vascularized epithelium, and proximity to the brain — features that make it an attractive route for peptides targeting either systemic or CNS effects.

When to Use

Intranasal delivery may be considered when:

• The peptide is specifically formulated for nasal administration (e.g., nasal spray devices with calibrated dose volumes)
• CNS delivery is desired, as the nasal route may provide preferential brain access for certain molecules
• A non-invasive, needle-free alternative to injection is preferred
• The peptide is of appropriate molecular size (generally below 10 kDa for reasonable nasal absorption)
• The research protocol specifically calls for intranasal dosing
• Rapid onset is desired — nasal absorption can be faster than subcutaneous injection for some peptides

Intranasal administration is not universally applicable. Many peptides have poor nasal bioavailability without permeation enhancers, and the nasal cavity has limited capacity for large volumes.

Technique/Process

Nasal Anatomy Relevant to Delivery

The nasal cavity is divided into three regions with different absorption characteristics:

• Vestibule — The outermost region, lined with keratinized epithelium. Poor absorption.
• Respiratory region — The largest region, lined with pseudostratified columnar epithelium and a rich vascular network. This is the primary site of systemic absorption.
• Olfactory region — Located at the roof of the nasal cavity. This small area (~10 cm2) provides a direct pathway to the brain via olfactory nerve axons.

Administration Procedure

1. Device selection — Use a calibrated nasal spray device that delivers a consistent volume per actuation (typically 100–200 microliters per spray). Metered-dose spray pumps are preferred over droppers for dose consistency.
2. Preparation — If the peptide is lyophilized, reconstitute according to the protocol. The solution must be compatible with nasal tissue (ideally isotonic, pH 4.5–6.5).
3. Nasal clearing — Gently blow the nose before administration to clear mucus that could impair absorption.
4. Head position — Tilt the head slightly forward (not backward) to direct the spray toward the respiratory mucosa rather than down the throat.
5. Administration — Insert the spray tip approximately 1 cm into the nostril. Direct the spray laterally (toward the ear on the same side) to target the respiratory mucosa. Actuate the device while inhaling gently.
6. Post-administration — Avoid sniffing forcefully, blowing the nose, or sneezing immediately after administration. Remain upright for several minutes.
7. Alternating nostrils — If the protocol requires more than one spray, alternate between nostrils to maximize mucosal coverage and reduce local irritation.

Dose Volumes

The nasal cavity has a limited capacity per administration:

• Maximum volume per nostril per application: approximately 150–200 microliters
• Larger volumes run posteriorly into the pharynx and are swallowed rather than absorbed nasally
• Total dose per administration event is typically limited to 200–400 microliters across both nostrils

Permeation Enhancers

Many peptide nasal formulations include permeation enhancers to improve absorption across the nasal epithelium. Common enhancers include cyclodextrins, chitosan, sodium taurodihydrofusidate, and bile salt derivatives. These agents transiently open tight junctions between epithelial cells or alter membrane fluidity to facilitate paracellular or transcellular transport.

Advantages/Disadvantages

Advantages

• Needle-free — improves acceptability and eliminates injection-related risks
• Avoids first-pass hepatic metabolism and GI degradation
• Rapid absorption — onset can occur within minutes
• Potential for nose-to-brain delivery, bypassing the blood-brain barrier
• Self-administration is straightforward with proper spray devices
• No requirement for sterile technique beyond standard aseptic handling

Disadvantages

• Variable bioavailability — typically 1–30% for peptides without permeation enhancers, highly dependent on formulation
• Nasal congestion, rhinitis, or mucosal damage can significantly alter absorption
• Limited dose volume restricts the amount of peptide that can be delivered per administration
• Mucociliary clearance rapidly removes deposited material (clearance half-time approximately 15–20 minutes)
• Potential for local irritation, especially with repeated use or permeation enhancers
• Dose reproducibility is lower than injection, as spray deposition varies with technique
• Enzymatic degradation by nasal mucosal peptidases can reduce effective dose

Safety

• Use only formulations specifically prepared for nasal administration — injectable formulations may contain preservatives or excipients that irritate nasal mucosa
• Monitor for signs of nasal irritation: dryness, burning, epistaxis (nosebleeds), or crusting
• Avoid nasal administration during active upper respiratory infections, as inflammation and excess mucus alter absorption unpredictably
• Osmolality of the nasal solution should be near isotonic (approximately 290 mOsm/kg) to minimize mucosal irritation
• Be aware that nasal bioavailability is typically much lower than injection bioavailability — dose adjustments are necessary and cannot be assumed from subcutaneous dosing data
• Long-term safety of permeation enhancers on nasal mucosal integrity requires monitoring

Related Topics

• Subcutaneous Injection — The standard injection route for most research peptides
• Oral Peptide Administration — Another non-injection route with distinct challenges
• Bioavailability — Typically lower for intranasal than injectable routes
• Reconstitution — Preparing peptide solutions for nasal delivery
• Osmolality — An important formulation parameter for nasal solutions